| Literature DB >> 16797679 |
Devansu Tewari1, Bahman Saffari, Carol Cowan, Anita C Wallick, M Zach Koontz, Bradley J Monk.
Abstract
BACKGROUND: The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors. CASE: A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16797679 DOI： 10.1016/j.ygyno.2006.04.025
Source DB: PubMed Journal: Gynecol Oncol ISSN： 0090-8258 Impact factor: 5.482